Contineum Therapeutics (CTNM) Equity Ratio (2023 - 2025)
Historic Equity Ratio for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to 0.95.
- Contineum Therapeutics' Equity Ratio fell 282.57% to 0.95 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.95, marking a year-over-year decrease of 282.57%. This contributed to the annual value of 0.93 for FY2024, which is 27859.67% up from last year.
- As of Q3 2025, Contineum Therapeutics' Equity Ratio stood at 0.95, which was down 282.57% from 0.94 recorded in Q2 2025.
- Over the past 5 years, Contineum Therapeutics' Equity Ratio peaked at 0.98 during Q2 2024, and registered a low of 0.61 during Q1 2024.
- In the last 3 years, Contineum Therapeutics' Equity Ratio had a median value of 0.93 in 2025 and averaged 0.57.
- In the last 5 years, Contineum Therapeutics' Equity Ratio surged by 27859.67% in 2024 and then tumbled by 462.72% in 2025.
- Over the past 3 years, Contineum Therapeutics' Equity Ratio (Quarter) stood at 0.52 in 2023, then surged by 278.6% to 0.93 in 2024, then grew by 1.62% to 0.95 in 2025.
- Its last three reported values are 0.95 in Q3 2025, 0.94 for Q2 2025, and 0.93 during Q1 2025.